ClinicalTrials.gg
RecruitingNCT06953323Updated Sep 17, 2026

A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors

A Phase 1/2 interventional study of WJB001 Capsules+Paclitaxel/Paclitaxel-albumin and WJB001 Capsules+carboplatin/Nedaplatin in Advanced Solid Tumor, sponsored by Wigen Biomedicine Technology (Shanghai) Co., Ltd.. Recruiting at 10 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Wigen Biomedicine Technology (Shanghai) Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
86
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a phase I/II study to preliminarily explore of the safety, tolerability, pharmacokinetics, and efficacy of WJB001 combination therapy, consisting of three stages: Dose escalation (Phase Ia), dose extension (Phase Ib), and efficacy extension (Phase II). The preliminary plan includes seven combination therapy regimens, namely Arm A: WJB001+taxanes (A1: WJB001+paclitaxel, A2: WJB001+albumin paclitaxel); Arm B: WJB001+platinum (B1: WJB001+carboplatin, B2: WJB001+nedaplatin); Arm C: WJB001+paclitaxel+carboplatin; Arm D: WJB001+PARP inhibitor; Arm E: WJB001+VEGF inhibitor; Arm F:WJB001+JS207/JS001(F1:WJB001+JS207,F2:WJB001+JS001);Arm G:WJB001+JS207/JS001+paclitaxel+carboplatin(G1: WJB001+JS207 +paclitaxel+carboplatin;G2:WJB001+JS001+paclitaxel+carboplatin).

Read the detailed description

The study is a multicenter,phase I/II clinical trial, divided into three parts:

In the Dose Escalation phase(Phase Ia): BOIN design were used to search the Maximum tolerated dose (MTD), allowing to increase or decrease the dose of one or separate drugs in the combination for dosage exploration.Recruitment by Arm, estimate 5 7 cohort, with several dose levels planned for each cohort:

In the Arm A/B/C combination therapy, chemotherapy (taxanes, platinum) is administered for a maximum of 6 cycles. After chemotherapy, WJB001 monotherapy is used to maintain treatment until the subject's disease progresses or withdrawl; In the Arm D combination therapy, the PARP inhibitor, such as Niraparib, is administered every 21 days in a cycle until the subject's disease progresses or withdrawl.

In the Arm E combination therapy, as an example, Bevacizumab can be treated for a maximum of 22 cycles or unacceptable side effects occur (whichever occurs first), and then Bevacizumab treatment is terminated and maintained with WJB001 monotherapy until the subject's disease progression or withdrawal In the Arm F1 combination therapy, JS207 is treated for 2 years or with unacceptable side effects (whichever occurs first) before disease progression occurs, and then JS207 treatment is terminated. Arm F2/G2: JS001 Treat until unacceptable side effects occur (whichever occurs first) before disease progression occurs.Upon termination of JS207/JS001 treatment, maintenance therapy with WJB001 monotherapy will be administered at a dose of 160 mg or the current dose (as determined by the investigator), until disease progression or withdrawal.

In the Arm G combination therapy, chemotherapy (paclitaxel, platinum) is administered for up to 6 cycles,WJB001+JS207/JS001 is maintained at the RP2D dose of the two drugs explored in Arm F or the current dose (determined by Investigator).

In the Dose Expansion phase(Phase Ib): 1 to 2 dose levels for each group will be selected the sponsor and the SMC based on the previous data, to further evaluate the preliminary efficacy, safety, tolerability and pharmacokinetic characteristics of the combination therapy in the target population, and confirm the RP2D dose of different combination regimens.

Efficacy Expansion Stage(Phase II): At the RP2D regimen determined in the Phase IB study, to explore the efficacy, safety, tolerability and pharmacokinetic characteristics of WJB001 combination therapy in the target population. And 2 to 3 cohorts is preliminarily planned for expansion and the "Simon Two-Stage" design is adopted.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Wigen Biomedicine Technology (Shanghai) Co., Ltd. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following inclusion criteria:

  1. Participants voluntarily participate in this study with full and sign an informed consent form(ICF).
  2. Age ≥ 18 years old, No gender limitation,witih (Body Mass Index) ≥ 18.5.
  3. Patients diagnosed with Advanced solid tumors confirmed by pathology and/or cytology, must meet the following criteria:

    1. For the detection of biomarkers such as CCNE1,tumor tissue samples must be provided from the patient
    2. CCNE1 overexpression confirmed by central laboratory immunohistochemistry (IHC) in tumor tissue
    3. Have failed or are intolerant to standard treatments or have no available standard treatments options(Applicable to Dose escalation phase)
    4. For patients with platinum-sensitive or platinum-resistant recurrent advanced high-grade serous ovarian cancer(HGSOC), fallopian tube cancer, or peritoneal cancer, as well as advanced uterine serous carcinoma (USC)
  4. There is at least one Target lesion that meets the definition of v1.1 criteria, and the selected target lesion has not received in the past two weeks.
  5. (ECOG) performance status score of 0 or 1.
  6. Expected survival time ≥12 week.
  7. Having Adequate hematologic and organ function, the following laboratory tests should be conducted within 7 days prior to the first administration of the drug (No blood transfusion, without receiving hematopoietic stimulating factors or human albumin preparations within 14 days prior to the examination):

    1. (ANC) ≥ 1.5 × 10\^9/L
    2. >90 g/L
    3. (AST) and alanine aminotransferase (ALT) ≤ 3.0 × (ULN)(for patients with liver ,AST and ALT≤ 5.0× ULN)
    4. Total (TBIL) ≤ 1.5 × ULN(for patients enrolled in Arm A,Arm C and Arm G , TBIL≤ 1.2.5× ULN;patients with Gilbert's Syndrome,TBIL≤3×ULN and Direct bilirubin≤ 1.5 × ULN)
    5. Serum creatinine(Cr) ≤1.5×ULN or (Ccr, calculated using Cockcroft-Gault formula) ≥45 mL/min (for patients enrolled in Arm B,Arm C and Arm G, Creatinine clearance ≥60 mL/min)
  8. All acute toxic reactions due to prior antitumor therapy or surgery have resolved to baseline level or grade ≤ 1 defined by V5.0 (except alopecia or pigmentation).
  9. The effective methods must be used.

Exclusion criteria

Exclusion Criteria:

Participants must not meet any of the following exclusion criteria:

  1. General condition.

    1. Pregnant or lactating women
    2. Any known allergies to or to components of the study drug
    3. History of substance abuse
    4. History of alcohol abuse or consumption of more than 28 units of alcohol per week (1 unit =285 ml beer or 25 ml spirits (40%v/v) or 100 ml wine)
  2. Previous or current treatment:

    1. Previous or current treatment with Wee1 inhibitors,as well as CDK2, PKMYT1, PARG, and ATR inhibitors
    2. Having received cytotoxic chemotherapy drugs, traditional Chinese medicine treatment indicated for anti-tumor purposes, or other anti-tumor drugs (such as small-molecule targeted therapy, etc.) within 14 days before the first administration of the study treatment; or having received drugs, macromolecular drugs with anti-tumor effects (such as monoclonal antibodies, antibody-drug conjugates, or bispecific antibodies, etc.) within 28 days before the first administration of the study treatment; or requiring continued treatment with these drugs during the study period
    3. Currently using moderate or strong inhibitors or inducers, or other products (such as grapefruit juice), or P-gp inhibitors or inducers, and the drug discontinuation time is less than 5 half-lives of the drug or 14 days (whichever is shorter) before the first administration of WJB001
    4. Known with having a organ transplant or stem cell transplant; Having major surgery or severe trauma (excluding needle for sample collection) within 4 weeks prior to the first administration of study drug;Minor surgery within 7 days before the first dose, excluding the placement of vascular infusion devices;
    5. Radiation therapy was administered within 21 days prior to the first administration of study drug, except for cases where radiation therapy is less than or equal to 5% of bone marrow volume, and regardless of when radiation therapy was received, the patients can be included in the study;Any local treatment for cancer such as thoracoabdominal perfusion therapy was received within 14 days before the first administration
    6. Poorly controlled pleural effusion, ascites, or pericardial effusion (poor control is defined as requiring puncture and drainage during the screening period or having undergone drainage within 3 months before the first dose of medication)
    7. Patients with a history of drug-related adverse events leading to permanent discontinuation during previous treatment with anti-PD-(L)1 antibodies or analogs or other therapies targeting the same pathway; (applicable only to Arm F and/or Arm G)
    8. Patients with a history of drug-related adverse events leading to permanent discontinuation during previous treatment with anti-VEGF monoclonal antibodies or analogs or other therapies targeting the same pathway; (applicable only to Arm E, F, and/or Arm G)
    9. Having received any or live-attenuated vaccine within 28 days prior to the first dose, or anticipated to require such vaccination during the study period
    10. Having received antiplatelet therapy within 10 days prior to the first dose (aspirin ≤325 mg/day is allowed) or anticoagulant therapy for treatment purposes (prophylactic anticoagulation is allowed);
    11. Patients with primary platinum- disease (defined as disease progression during the first platinum-containing regimen or within 4 weeks)
  3. Past medical history, present medical history and abnormal laboratory indicators:

    1. Having active gastrointestinal abnormalities including, but not limited to, inability to take oral medication, need for intravenous nutritional support, peptic ulcer, chronic diarrhea (e.g., Crohn's disease, irritable bowel syndrome), or vomiting or other factors that the investigator deems may significantly affect absorption, metabolism, or excretion of the drug (such as a small intestinal stoma, etc.)
    2. There was a history of severe eye diseases in the past (excluding permanent blindness caused by the disease), and it has not been recovered Grade ≤1 at present
    3. Patients with active (except if they have central nervous system (CNS) confined to the supratentorial or cerebellar region, having received adequately treatment (surgery or radiotherapy), having maintained radiological stability for at least 4 weeks, and do not require for symptom control)
    4. Patients currently have suffered carcinomatous meningitis, spinal cord compression, and hepatic encephalopathy, etc
    5. Severe or poorly controlled hypertension, including a history of hypertensive crisis or hypertensive encephalopathy; having Adjustment of antihypertensive medication due to poor blood pressure control within 2 weeks before the first dose;Systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg during the screening period
    6. Having any of the following cardiac criteria: cardiomyopathy, ischemic heart disease, valvular disease, hypertensive heart disease, heart failure, presyncope or syncope of unexplained or cardiovascular origin, ventricular tachycardia, ventricular fibrillation, or cardiac arrest. At rest, the average interval (QTc, calculated using Fridericia's correction formula) obtained from three (ECG) examinations is >450 ms for males or >470 ms for females (repeated three times). Various arrhythmias, conduction abnormalities, and resting ECG morphological abnormalities, such as complete left bundle branch block, third-degree atrioventricular block, second-degree atrioventricular block, PR interval >250 ms. Echocardiography shows that the (LVEF) \< 50%. Various factors that may increase the risk of QTc prolongation or arrhythmia events, such as heart failure, hypokalemia, a history of congenital long QT syndrome or torsades de pointes (TdP), a family history of long QT syndrome in a direct relative or sudden unexplained death of a direct relative before the age of 40, and currently using any drug known to prolong the QT interval
    7. Having clinically significant bleeding symptoms or obvious bleeding tendency within 4 weeks before the first dose, such as gastrointestinal bleeding, gastric ulcer bleeding, obvious gross hematuria, or suffering from vasculitis,etc; Or have evidence of major coagulation disorders within 6 months before the first administration of the drug, such as events like deep vein thrombosis of the lower extremities, myocardial infarction, etc
    8. Having active and infection: if HBsAg is positive or/and anti-HBC is positive, blood HBV DNA need to be tested to confirm that it is higher than the limit of quantitative detection; If anti-HCV is positive, HCV RNA need to be tested to confirm that the HCV viral copy number exceeds the quantitative detection limit
    9. known history of infection or having a positive result for serum anti-HIV test
    10. History of other primary solid tumor(except for the radically cured solid tumor ,which is inactive and has a very low risk of recurrence for ≥5 years before screening); Non-melanoma skin cancer or lentigo maligna that has been adequately treated andshows no evidence of disease recurrence; Carcinoma in situ, such as cervical carcinoma in situ, that has been adequately treated and shows no evidence of disease recurrence)
    11. Severe active infectious diseases or other diseases that seriously affect the safety of the first medication occurred during the screening period
    12. Within 2 years prior to the first use of medication, there are active diseases that require systemic treatment (such as corticosteroids or drugs), including but not limited to: systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, vasculitis, etc. However, screening is allowed for hypothyroidism, adrenal or pituitary dysfunction, type I diabetes that can be controlled only by hormone replacement therapy, psoriasis or vitiligo that does not need systematic treatment, and childhood asthma/allergy that has been cured
    13. History of interstitial lung disease or history of non infectious pneumonia and treatment with corticosteroids, or screening imaging showing evidence of active pneumonia
    14. The investigator deems that the patient has other factors that may affect the research results and interfere with their participation in the entire research process. These factors include, but are not limited to, past or current physical conditions (such as mental disorders, optic nerve atrophy, excessive low body weight, severe hydronephrosis, or thyroid dysfunction), treatments, or abnormal laboratory test results. The subject is unwilling to abide by various procedures, restrictions, and requirements of the study, is unable to cooperate or undergo MRI or CT scans, or has psychological or social conditions that may interfere with their participation in the study or have an impact on the evaluation of the study results, etc
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
86 participants (estimated)

Study arms

  • Experimental
    WJB001 capsules with Taxanes

    If needed, additional descriptive information (including which interventions are administered in each arm) to differentiate each arm from other arms in the clinical trial. Phase Ia: Participants with advanced solid tumor will receive WJB001 capsules at escalating dose levels after a maximum of 6 cycles of Paclitaxel/Paclitaxel-albumin. Phase Ib/II: Participants with High-grade serous ovarian cancer(HGSOC),fallopian tube cancer,peritoneal cancer ,or Uterine Serous Carcinoma(USC) will receive WJB001 capsules at expansion dose levels after a maximum of 6 cycles of carboplatin/Nedaplatin.

    Drug: WJB001 Capsules+Paclitaxel/Paclitaxel-albumin

  • Experimental
    WJB001 capsules with Platinum

    If needed, additional descriptive information (including which interventions are administered in each arm) to differentiate each arm from other arms in the clinical trial. Phase Ia: Participants with advanced solid tumor will receive WJB001 capsules at escalating dose levels after a maximum of 6 cycles of carboplatin/Nedaplatin. Phase Ib/II: Participants with High-grade serous ovarian cancer(HGSOC),fallopian tube cancer,peritoneal cancer ,or Uterine Serous Carcinoma(USC) will receive WJB001 capsules at expansion dose levels after a maximum of 6 cycles of carboplatin/Nedaplatin.

    Drug: WJB001 Capsules+carboplatin/Nedaplatin

  • Experimental
    WJB001 capsules with paclitaxel+carboplatin

    If needed, additional descriptive information (including which interventions are administered in each arm) to differentiate each arm from other arms in the clinical trial. Phase Ia: Participants with advanced solid tumor will receive WJB001 capsules at escalating dose levels after a maximum of 6 cycles of Paclitaxel+carboplatin. Phase Ib/II: Participants with High-grade serous ovarian cancer(HGSOC),fallopian tube cancer,peritoneal cancer ,or Uterine Serous Carcinoma(USC) will receive WJB001 capsules at expansion dose levels iafter a maximum of 6 cycles of Paclitaxel+carboplatin.

    Drug: WJB001 Capsules+Paclitaxel+carboplatin

  • Experimental
    WJB001 capsules with PARPi

    If needed, additional descriptive information (including which interventions are administered in each arm) to differentiate each arm from other arms in the clinical trial. Phase Ia: Participants with advanced solid tumor will receive WJB001 capsules at escalating dose levels in combination with PAPPi. Phase Ib/II: Participants with High-grade serous ovarian cancer,fallopian tube cancer(HGSOC),peritoneal cancer ,or Uterine Serous Carcinoma(USC) will receive WJB001 capsules at expansion dose levels in combination with PAPPi.

    Drug: WJB001 Capsules+Niraparib

  • Experimental
    WJB001 capsules with VEGFi

    If needed, additional descriptive information (including which interventions are administered in each arm) to differentiate each arm from other arms in the clinical trial. Phase Ia: Participants with advanced solid tumor will receive WJB001 capsules at escalating dose levels in combination with VEGFi. Phase Ib/II: Participants with High-grade serous ovarian cancer(HGSOC),fallopian tube cancer,peritoneal cancer ,or Uterine Serous Carcinoma(USC) will receive WJB001 capsules at expansion dose levels in combination with VEGFi.

    Drug: WJB001 Capsules+Bevacizumab

  • Experimental
    WJB001 capsules with Anti-PD-1 and VEGF bispecific antibodies/ Anti-PD-1 antibodies

    If needed, additional descriptive information (including which interventions are administered in each arm) to differentiate each arm from other arms in the clinical trial. Phase Ia: Participants with advanced solid tumor will receive WJB001 capsules at escalating dose levels in combination with Anti-PD-1 and VEGF bispecific antibodies/ Anti-PD-1 antibodies . Phase Ib/II: Participants with High-grade serous ovarian cancer(HGSOC),fallopian tube cancer,peritoneal cancer ,or Uterine Serous Carcinoma(USC) will receive WJB001 capsules at expansion dose levels in combination with Anti-PD-1 and VEGF bispecific antibodies/ Anti-PD-1 antibodies.

    Drug: WJB001 Capsules+JS207/JS001

  • Experimental
    WJB001 capsules with paclitaxel and carboplatin, together with Anti-PD-1 and VEGF bispecific antibo

    If needed, additional descriptive information (including which interventions are administered in each arm) to differentiate each arm from other arms in the clinical trial. Phase Ia:Participants with advanced solid tumor will receive WJB001 capsules in combination with paclitaxel and carboplatin, together with Anti-PD-1 and VEGF bispecific antibodies/ Anti-PD-1 antibodies . Phase Ib and II:Participants with High-grade serous ovarian cancer,fallopian tube cancer,peritoneal cancer ,or Uterine Serous Carcinoma will receive WJB001 capsules in combination with paclitaxel and carboplatin, together with Anti-PD-1 and VEGF bispecific antibodies/ Anti-PD-1 antibodies .

    Drug: WJB001 Capsules+Paclitaxel+carboplatin+JS207/Toripalimab

Interventions

  • DrugWJB001 Capsules+Paclitaxel/Paclitaxel-albumin

    WJB001 Capsules:120mg(or 160mg,80mg,40mg,or 100mg,60mg),Oral,QD,Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days; Paclitaxel:80 mg/m2(or 60 mg/m2 ,50 mg/m2), Day 1, day 8, day 15, intravenous infusion, 21 days 1 cycle, up to 6 cycles; Paclitaxel-albumin:260mg/m2(220mg/m2,180mg/m2),On day 1, intravenous infusion, 21 days 1 cycle, up to 6 cycles

    Also known as: Wee1 inhibitor+ Taxol/Abraxane

  • DrugWJB001 Capsules+carboplatin/Nedaplatin

    WJB001 Capsules:80mg(or160mg, 120mg,40mg,or 100mg,60mg),Oral,QD,Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days; Carboplatin:AUC 5 mg/ml\*min(or 4mg/ml\*min,3mg/ml\*min), Day 1, day 8, day 15, intravenous infusion, 21 days 1 cycle, up to 6 cycles; Nedaplatin:100mg(80mg/m2 ,60mg/m2), Day 1, intravenous infusion, 21 days 1 cycle, up to 6 cycles;

    Also known as: Wee1 inhibitor+ PARAPLATIN/Aqupla

  • DrugWJB001 Capsules+Paclitaxel+carboplatin

    WJB001 Capsules:40mg(or 160mg, 120 mg,80mg,60mg,or 100mg,60mg),Oral,QD,Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days; Paclitaxel:60 mg/m2, Day 1, day 8, day 15, intravenous infusion, 21 days 1 cycle, up to 6 cycles; Carboplatin:AUC 2mg/ml\*min, Day 1, day 8, day 15, intravenous infusion, 21 days 1 cycle, up to 6 cycles;

    Also known as: Wee1 inhibitor+ PARAPLATIN+Taxol

  • DrugWJB001 Capsules+Niraparib

    WJB001 Capsules:120mg(or 160mg,80mg,40mg,or 100mg,60mg),Oral,QD,Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days; Niraparib:Niraparib:300mg(or 200mg,100mg),Oral,QD,Every 21 days;

    Also known as: Wee1 inhibitor+ Zejula

  • DrugWJB001 Capsules+Bevacizumab

    WJB001 Capsules:120mg(or 160mg,80mg,40mg,or 100mg,60mg),Oral,QD,Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days; Bevacizumab:15mg/kg(or 7.5mg/kg),intravenous infusion, 21 days 1 cycle, up to 22 cycles or unacceptable side effects;

    Also known as: Wee1 inhibitor+ Avastin

  • DrugWJB001 Capsules+JS207/JS001

    WJB001 Capsules:120mg/160mg ( (or referring to previously conducted cohorts or other clinical studies ),Oral,QD,Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days; JS207:10mg/kg(or lower dosage),intravenous infusion, 21 days 1 cycle, up to 2 years or unacceptable side effects; Toripalimab:240 mg,intravenous infusion,21 days 1 cycle, up to desease progression or unacceptable side effects;

    Also known as: Wee1 inhibitor+JS207/Toripalimab

  • DrugWJB001 Capsules+Paclitaxel+carboplatin+JS207/Toripalimab

    Drug pages: Paclitaxel · Carboplatin · Anti-PD-1/Anti-VEGF Bispecific Antibody JS207 · Toripalimab

    WJB001 Capsules:40mg (or referring to previously conducted cohorts or other clinical studies ),Oral,QD,Days 1-5, 8-12, 15-19 or other dosing frequencies (e.g., days 1-4, 8-11, 15-18),Every 21 days; JS207:10mg/kg(or lower dosage),intravenous infusion, 21 days 1 cycle, up to 2 years or unacceptable side effects Toripalimab:240 mg,intravenous infusion,21 days 1 cycle, up to desease progression or unacceptable side effects Paclitaxel:60 mg/m2, Day 1, day 8, day 15, intravenous infusion, 21 days 1 cycle, up to 6 cycles; Carboplatin:AUC 2mg/ml\*min, Day 1, day 8, day 15, intravenous infusion, 21 days 1 cycle, up to 6 cycles;

This study also gives Niraparib. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Dose limited toxicity (DLT)

    Incidence of Dose limited toxicity(DLT)

    Time frame: 21day

  2. Adverse event (AE)

    Incidence and severity of adverse event (AE), Abnormal changes in laboratory and other tests of clinical significance

    Time frame: 3 years

  3. Serious adverse event (SAE)

    Incidence and severity of Serious adverse event (SAE)

    Time frame: 3 years

  4. Maximum tolerated dose (MTD)

    Maximum tolerated dose (MTD)

    Time frame: 2 years

  5. Recommended phase II dose (RP2D)

    Recommended phase II dose (RP2D)

    Time frame: 2 years

  6. Objective response rate(ORR)

    Objective response rate(ORR) evaluated by Investigator per RECIST v1.1 in Phase II

    Time frame: 3 years

Secondary outcomes

  1. Peak time(Tmax)

    Pharmacokinetic (PK) parameter : Peak time(Tmax) after a single dose of WJB001/JS207;

    Time frame: 4 Months

  2. Maximum plasma concentration (Cmax)

    Maximum plasma concentration (Cmax) after a single dose of WJB001/JS207;

    Time frame: 4 Months

  3. (AUC 0-t)

    Area under blood concentration - time curve(AUC 0-t) after a single dose of WJB001/JS207;

    Time frame: 4 Months

  4. (AUC 0-∞)

    Area under blood concentration - time curve(AUC 0-∞) after a single dose of WJB001/JS207;

    Time frame: 4 Months

  5. Apparent volume of distribution (Vd/F)

    Apparent volume of distribution (Vd/F) after a single dose of WJB001/JS207;

    Time frame: 4 Months

  6. Clearance rate (CL/F)

    Clearance rate (CL/F) after a single dose of WJB001/JS207;

    Time frame: 4 Months

  7. Elimination half-life time ( t1/2)

    Elimination half-life time ( t1/2) after a single dose of WJB001/JS207;

    Time frame: 4 Months

  8. Steady state peak concentration(Cmax,ss)

    Steady state peak concentration(Cmax,ss) after multiple administration for WJB001/JS207;

    Time frame: 4 Months

  9. Steady state valley concentration(Cmin,ss)

    Steady state valley concentration(Cmin,ss) after multiple administration for WJB001/JS207;

    Time frame: 4 Months

  10. Average steady-state plasma concentration(Cav,ss)

    Average steady-state plasma concentration(Cav,ss) after multiple administration for WJB001/JS207;

    Time frame: 4 Months

  11. Steady state peak time(Tmax,ss)

    Steady state peak time(Tmax,ss) after multiple administration for WJB001/JS207;

    Time frame: 4 Months

  12. Steady state Area under blood concentration - time curve(AUC0-t,ss)

    Steady state Area under blood concentration - time curve(AUC0-t,ss) after multiple administration for WJB001/JS207;

    Time frame: 4 Months

  13. Accumulation Index ( RAC)

    Accumulation Index ( RAC) after multiple administration for WJB001/JS207;

    Time frame: 4 Months

  14. Anti-drug antibodies (ADA)

    Incidence and titer of anti-drug antibodies (ADA) for JS207;

    Time frame: 2 years

  15. Neutralizing Antibody (NAb)

    Incidence of Antibody (NAb) for JS207

    Time frame: 2 years

  16. Objective response rate(ORR)

    Objective response rate(ORR) evaluated by Investigator per RECIST v1.1 in Phase I

    Time frame: 3 years

  17. Duration of response (DOR)

    Efficacy endpoints : Duration of response (DOR) evaluated by Investigator per RECIST v1.1

    Time frame: 3 years

  18. Disease control rate (DCR)

    Efficacy endpoints: Disease control rate (DCR) evaluated by Investigator per RECIST v1.1;

    Time frame: 3 years

  19. Time of Disease Progression (TTP)

    Time of Disease Progression (TTP) evaluated by Investigator per RECIST v1.1

    Time frame: 3 years

  20. Progression-free survival (PFS)

    Progression-free survival (PFS) evaluated by Investigator per RECIST v1.1

    Time frame: 3 years

  21. Overall survival (OS)

    Overall survival (OS) evaluated by Investigator per RECIST v1.1

    Time frame: 3 years

  22. CCNE1

    The correlation between CCNE1 overexpression or amplification and therapeutic efficacy

    Time frame: 3 years

Other outcomes

  1. Biomarkers

    The incidence of biomarkers (such as DNA damage repair and cell cycle related gene variations, PD-L1 expression) in target tumor species and their correlation with therapeutic efficacy

    Time frame: 3 years

07

Study locations

10 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Jun 2029, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2025
First posted
May 1, 2025
StartActual
Jul 10, 2025
Primary completionEst.
Jun 30, 2029
CompletionEst.
Dec 30, 2029
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06953323
Lead sponsor
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Responsible party
Sponsor
First posted
May 1, 2025
Start date
Jul 10, 2025
Primary completion
Jun 30, 2029 (estimated)
Completion
Dec 30, 2029 (estimated)
Last update
Sep 17, 2026

Study contacts

Yirong Zhao, Master
Contact
yrzhao@wigenbio.com
15221069447

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Paclitaxel · Carboplatin · Anti-PD-1/Anti-VEGF Bispecific Antibody JS207 · Toripalimab

Other studies from this sponsor

Wigen Biomedicine Technology (Shanghai) Co., Ltd.

Start the discussion